Yurii Husiev

Yurii Husiev

Auto-generated profile, based on publicly available information

Yurii Husiev

National Aerospace University "Kharkiv Aviation Institute", Kharkiv

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in Journal of the American Chemical Society
Verified
Journal Article
Open access
LZLiyan Zhang
Liyan Zhang
PWPeiyuan Wang
Peiyuan Wang
XZXue-Quan Zhou
Xue-Quan Zhou
LBLudovic BRETIN
Ludovic BRETIN
XZXiaolong Zeng
Xiaolong Zeng
SBSylvestre Bonnet
Sylvestre Bonnet
To investigate the potential of tumor-targeting photoactivated chemotherapy, a chiral ruthenium-based anticancer warhead, Λ/Δ-[Ru(Ph2phen)2(OH2)2]2+, was conjugated to the RGD-containing Ac-MRGDH-NH2 peptide by direct coordination of the M and H residues to the metal. This design afforded two diastereoisomers of a cyclic metallopeptide, Λ-[1]Cl2 and Δ-[1]Cl2. In the dark, the ruthenium-chelating peptide had a triple action. First, it prevented other biomolecules from coordinating with the metal center. Second, its hydrophilicity made [1]Cl2 amphiphilic so that it self-assembled in culture medium into nanoparticles. Third, it acted as a tumor-targeting motif by strongly binding to the integrin (Kd = 0.061 μM for the binding of Λ-[1]Cl2 to αIIbβ3), which resulted in the receptor-mediated uptake of the conjugate in vitro. Phototoxicity studies in two-dimensional (2D) monolayers of A549, U87MG, and PC-3 human cancer cell lines and U87MG three-dimensional (3D) tumor spheroids showed that the two isomers of [1]Cl2 were strongly phototoxic, with photoindexes up to 17. Mechanistic studies indicated that such phototoxicity was due to a combination of photodynamic therapy (PDT) and photoactivated chemotherapy (PACT) effects, resulting from both reactive oxygen species generation and peptide photosubstitution. Finally, in vivo studies in a subcutaneous U87MG glioblastoma mice model showed that [1]Cl2 efficiently accumulated in the tumor 12 h after injection, where green light irradiation generated a stronger tumoricidal effect than a nontargeted analogue ruthenium complex [2]Cl2. Considering the absence of systemic toxicity for the treated mice, these results demonstrate the high potential of light-sensitive integrin-targeted ruthenium-based anticancer compounds for the treatment of brain cancer in vivo.

16 May 2022 in Chemical Science
Verified
Journal Article
Open access
PDF file
QCQuanchi Chen
Quanchi Chen
JCJordi-Amat Cuello-Garibo
Jordi-Amat Cuello-Garibo
LBLudovic Bretin
Ludovic Bretin
LZLiyan Zhang
Liyan Zhang
VRVadde Ramu
Vadde Ramu
SBSylvestre Bonnet
Sylvestre Bonnet
In vivo data are rare but essential for establishing the clinical potential of ruthenium-based photoactivated chemotherapy (PACT) compounds, a new family of phototherapeutic drugs that are activated via ligand photosubstitution. Here a novel trisheteroleptic ruthenium complex [Ru(dpp)(bpy)(mtmp)](PF6)2 ([2](PF6)2, dpp = 4,7-diphenyl-1,10-phenanthroline, bpy = 2,2′-bipyridine, mtmp = 2-methylthiomethylpyridine) was synthesized and its light-activated anticancer properties were validated in cancer cell monolayers, 3D tumor spheroids, and in embryonic zebrafish cancer models. Upon green light irradiation, the non-toxic mtmp ligand is selectively cleaved off, thereby releasing a phototoxic ruthenium-based photoproduct capable notably of binding to nuclear DNA and triggering DNA damage and apoptosis within 24–48 h. In vitro, fifteen minutes of green light irradiation (21 mW cm−2, 19 J cm−2, 520 nm) were sufficient to generate high phototherapeutic indexes (PI) for this compound in a range of cancer cell lines including lung (A549), prostate (PC3Pro4), conjunctival melanoma (CRMM1, CRMM2, CM2005.1) and uveal melanoma (OMM1, OMM2.5, Mel270) cancer cell lines. The therapeutic potential of [2](PF6)2 was further evaluated in zebrafish embryo ectopic (PC3Pro4) or orthotopic (CRMM1, CRMM2) tumour models. The ectopic model consisted of red fluorescent PC3Pro4-mCherry cells injected intravenously (IV) into zebrafish, that formed perivascular metastatic lesions at the posterior ventral end of caudal hematopoietic tissue (CHT). By contrast, in the orthotopic model, CRMM1- and CRMM2-mCherry cells were injected behind the eye where they developed primary lesions. The maximally-tolerated dose (MTD) of [2](PF6)2 was first determined for three different modes of compound administration: (i) incubating the fish in prodrug-containing water (WA); (ii) injecting the prodrug intravenously (IV) into the fish; or (iii) injecting the prodrug retro-orbitally (RO) into the fish. To test the anticancer efficiency of [2](PF6)2, the embryos were treated 24 h after engraftment at the MTD. Optimally, four consecutive PACT treatments were performed on engrafted embryos using 60 min drug-to-light intervals and 90 min green light irradiation (21 mW cm−2, 114 J cm−2, 520 nm). Most importantly, this PACT protocol was not toxic to the zebrafish. In the ectopic prostate tumour models, where [2](PF6)2 showed the highest photoindex in vitro (PI > 31), the PACT treatment did not significantly diminish the growth of primary lesions, while in both conjunctival melanoma orthotopic tumour models, where [2](PF6)2 showed more modest photoindexes (PI ∼ 9), retro-orbitally administered PACT treatment significantly inhibited growth of the engrafted tumors. Overall, this study represents the first demonstration in zebrafish cancer models of the clinical potential of ruthenium-based PACT, here against conjunctival melanoma.

9 December 2024 in ACS Central Science
Verified
Journal Article
Open access
LZLiyan Zhang
Liyan Zhang
GZGangyin Zhao
Gangyin Zhao
TDTrevor Dalrymple
Trevor Dalrymple
YHYurii Husiev
Yurii Husiev
HBHildert Bronkhorst
Hildert Bronkhorst
SBSylvestre Bonnet
Sylvestre Bonnet
The blood-brain barrier (BBB) presents one of the main obstacles to delivering anticancer drugs in glioblastoma. Herein, we investigated the potential of a series of cyclic ruthenium-peptide conjugates as photoactivated therapy candidates for the treatment of this aggressive tumor. The three compounds studied, Ru-p(HH), Ru-p(MH), and Ru-p(MM) ([Ru(Ph2phen)2 (Ac-X1RGDX2-NH2)]Cl2 with Ph2phen = 4,7-diphenyl-1,10-phenanthroline and X1, X2 = His or Met), include an integrin-targeted pentapeptide coordinated to a ruthenium warhead via two photoactivated ruthenium-X1,2 bonds. Their photochemistry, activation mechanism, tumor targeting, and antitumor activity were meticulously addressed. A combined in vitro and in vivo study revealed that the photoactivated cell-killing mechanism and their O2 dependence were strongly influenced by the nature of X1 and X2. Ru-p(MM) was shown to be a photoactivated chemotherapy (PACT) drug, while Ru-p(HH) behaved as a photodynamic therapy (PDT) drug. All conjugates, however, showed comparable antitumor targeting and efficacy toward human glioblastoma 3D spheroids and orthotopic glioblastoma tumor models in zebrafish embryos. Most importantly, in this model, all three compounds could effectively cross the BBB, resulting in excellent targeting of the tumors in the brain.

18 November 2025 in Journal of the American Chemical Society
Verified
Journal Article
Open access
YHYurii Husiev
Yurii Husiev
SGSina Katharina Götzfried
Sina Katharina Götzfried
MHMatthijs L. A. Hakkennes
Matthijs L. A. Hakkennes
DKDaria Kotova
Daria Kotova
INIsabelle Tutein Nolthenius
Isabelle Tutein Nolthenius
SBSylvestre Bonnet
Sylvestre Bonnet
Herein we report a novel ruthenium-based photocage for photoactivated chemotherapy (PACT) that can deliver a variety of experimental and clinically approved anticancer drugs using red and far-red light. The new caging moiety is based on the polypyridine pentadentate ligand N6,N6″-di(pyridin-2-yl)-[2,2':6',2″-terpyridine]-6,6″-diamine (baptpy), which once coordinated to ruthenium(II) can form the helically chiral [Ru(baptpy)(L)]X2 prodrugs [6]Cl2-[16]Cl2. A total of ten active pharmaceutical ingredients (L) have been successfully conjugated to this photocage, including well-known agents such as Albendazole, Gemcitabine, Bosutinib, Neratinib, and Ponatinib. The X-ray crystal structures of seven complexes were obtained, showing coordination of ligand L via its thioether, nitrile, pyridine or imidazole moieties. All prepared ruthenium compounds showed selective photosubstitution of the monodentate ligand under 625 (red) and 730 nm (far-red) light irradiation with good (0.005-0.05) to excellent (0.05-0.10) quantum yields, while no singlet oxygen generation was observed. As calculated by density functional theory and time-dependent density functional theory, the high-wavelength light absorption of [Ru(baptpy)(L)]X2 complexes and their favorable ligand exchange behavior under low-energy light are the consequence of the strong distortion of the first coordination sphere, combined with the electronic effect of the amine bridges of the baptpy ligand. Preliminary biological activity of complexes [6]Cl2-[16]Cl2 was investigated in vitro by cytotoxicity studies in the dark and under red light irradiation in normoxic A375 and U-87MG human cancer cell lines. Several of the obtained PACT prodrugs exhibited micro- to nanomolar EC50 values upon red light activation, with photoindexes as high as 7.5. [7]Cl2 showed a photoindex of 6.2 upon far-red light activation (730 nm), which is unprecedented for a ruthenium-based PACT, while the ruthenium cage itself showed very low toxicity in both the dark and light irradiation.

1 December 2022 in Photochemistry and Photobiology
Verified
Journal Article
Open access
EGErik Pieter van Geest
Erik Pieter van Geest
SGSina Katharina Götzfried
Sina Katharina Götzfried
DKDavid M. Klein
David M. Klein
NSNadiya Salitra
Nadiya Salitra
SPSorraya Popal
Sorraya Popal
SBSylvestre Bonnet
Sylvestre Bonnet
Photosubstitutionally active ruthenium complexes show high potential as prodrugs for the photoactivated chemotherapy (PACT) treatment of tumors. One of the problems in PACT is that the localization of the ruthenium compound is hard to trace. Here, a ruthenium PACT prodrug, [Ru(3)(biq)(STF‐31)](PF6)2 (where 3 = 3‐(([2,2′:6′,2″‐ter‐ pyridin]‐4′‐yloxy)propyl‐4‐(pyren‐1‐yl)butanoate) and biq = 2,2′‐biquinoline), has been prepared, in which a pyrene tracker is attached via an ester bond. The proximity between the fluorophore and the ruthenium center leads to fluorescence quenching. Upon intracellular hydrolysis of the ester linkage, however, the fluorescence of the pyrene moiety is recovered, thus demonstrating prodrug cellular uptake. Further light irradiation of this molecule liberates by photosubstitution STF‐31, a known cytotoxic nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, as well as singlet oxygen via excitation of the free pyrene chromophore. The dark and light cytotoxicity of the prodrug, embedded in liposomes, as well as the appearance of blue emission upon uptake, were evaluated in A375 human skin melanoma cells. The cytotoxicity of the liposome‐embedded prodrug was indeed increased by light irradiation. This work realizes an in vitro proof‐of‐concept of the lock‐and‐kill principle, which may ultimately be used to design strategies aimed at knowing where and when light irradiation should be realized in vivo.

26 June 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SASelda Abyar
Selda Abyar
LHLuojiao Huang
Luojiao Huang
YHYurii Husiev
Yurii Husiev
LBLudovic BRETIN
Ludovic BRETIN
BCBobby Chau
Bobby Chau
SBSylvestre Bonnet
Sylvestre Bonnet
Photoactivated chemotherapy agents form a new branch of physically targeted anticancer agents with potentially lower systemic side effects for patients. On the other hand, limited information exists on the intracellular interactions between the photoreleased metal cage and the photoreleased anticancer inhibitor. In this work, we report a new biological study of the known photoactivated compound Ru-STF31 in the glioblastoma cancer cell line, U87MG. Ru-STF31 targets nicotinamide phosphoribosyltransferase (NAMPT), an enzyme overexpressed in U87MG. Ru-STF31 is activated by red light irradiation and releases two photoproducts: the ruthenium cage and the cytotoxic inhibitor STF31. This study shows that Ru-STF31 can significantly decrease intracellular NAD+ levels in both normoxic (21% O2) and hypoxic (1% O2) U87MG cells. Strikingly, NAD+ depletion by light activation of Ru-STF31 in hypoxic U87MG cells could not be rescued by the addition of extracellular NAD+. Our data suggest an oxygen-dependent active role of the ruthenium photocage released by light activation.